Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Fabien Diomandé"'
Autor:
Patrick L.F. Zuber, Bartholomew Dicky Akanmori, Samba O. Sow, Téné M. Yaméogo, Modibo Keita, Mamoudou Harouna Djingarey, Simonetta Viviani, Nehemie Mbakuliyemo, Kirsten S. Vannice, Fabien Diomandé, Marie-Pierre Preziosi, Claude-Roger Ouandaogo
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
A group A meningococcal conjugate vaccine, PsA-TT, was developed by the Meningitis Vaccine Project and the Serum Institute of India, Ltd (SIIL). Clinical trials conducted among approximately 10 000 persons aged 1–29 years, in India and in Africa, c
Autor:
Jennifer Dolan Thomas, Paul A. Kristiansen, Denis Kandolo, Marie-Pierre Préziosi, F. Marc LaForce, Abdoul-Salam Ouédraogo, Rasmata Ouédraogo, Thomas A. Clark, Absatou Ky Ba, Dominique A. Caugant, Idrissa Sanou, Fabien Diomandé, Lassana Sangaré
Publikováno v:
Journal of Clinical Microbiology. 50:4020-4027
Neisseria lactamica is a true commensal bacterium occupying the same ecological niche as the pathogenic Neisseria meningitidis , which is responsible for outbreaks and large epidemics, especially in sub-Saharan Africa. To better understand the epidem
Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity
Autor:
Absatou Ky Ba, Marie-Pierre Préziosi, Stacey W. Martin, Paul A. Kristiansen, Inger Marie Saga, Mamoudou Harouna Djingarey, Abdoul Salam Ouedraogo, Jennifer Dolan Thomas, Fabien Diomandé, Lassana Sangaré, Flavien Aké, Rasmata Ouédraogo, Sylvestre R. M. Tiendrebéogo, Thomas A. Clark, Denis Kandolo, Nancy E. Messonnier, Lara K. Misegades, F. Marc LaForce, Musa Hassan-King, Dominique A. Caugant, Idrissa Sanou
Publikováno v:
Clinical Infectious Diseases. 56:354-363
Background The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of 1-29-year-olds in Burkina Faso in 2010. It is not known whether MenAfriVac has an impact on NmA carri
Autor:
Leonard W. Mayer, Stacey W. Martin, Tiga F. Tarbangdo, Ryan T. Novak, Fenella Avokey, Clement Lingani, Cynthia Hatcher, Lassana Sangaré, Sylvestre R. M. Tiendrebéogo, Jean Ludovic Kambou, F. Marc LaForce, Nancy E. Messonnier, Fabien Diomandé, Thomas A. Clark, Rasmata Ouédraogo-Traoré, Mamoudou Harouna Djingarey
Publikováno v:
The Lancet Infectious Diseases. 12:757-764
An affordable, highly immunogenic Neisseria meningitidis serogroup A meningococcal conjugate vaccine (PsA-TT) was licensed for use in sub-Saharan Africa in 2009. In 2010, Burkina Faso became the first country to implement a national prevention campai
Autor:
Clement Lingani, Mamoudou Harouna Djingarey, Denis Kandolo, Ryan T. Novak, William Perea, Rodrigue Barry, Fabien Diomandé, Carol Tevi-Benissan, Florence Shirehwa, Marie-Pierre Preziosi, F. Marc LaForce
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background. A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically for the African “meningitis belt” and was prequalified by the World Health Organization (WHO) in June 2010. The vaccine was first used widely in Burkina Fas
Autor:
Patrick L.F. Zuber, Samba O. Sow, Téné M. Yaméogo, Lawrence H. Moulton, Uma Onwuchekwa, Modibo Keita, Anna P. Durbin, Massambou Sacko, Neal A. Halsey, Kirsten S. Vannice, Saad B. Omer, Fabien Diomandé
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
New vaccines, such as those against malaria and dengue, are being developed for use primarily in low-resource countries. Emerging manufacturers provide an increasingly large volume of vaccine products to global programs that will never reach industri
Autor:
Marc LaForce, Lassana Sangaré, Jennifer Dolan Thomas, Pascal Kaboré, Rasmata Ouédraogo, Denis Kandolo, Paul A. Kristiansen, Mamoudou Harouna Djingarey, Marie-Pierre Préziosi, Abdoul-Salam Ouédraogo, Thomas A. Clark, Nancy E. Messonnier, Charles D. Ouédraogo, Cynthia Hatcher, Musa Hassan-King, Stanley C. Wei, Fabien Diomandé, Dominique A. Caugant, Idrissa Sanou, Ki Ba Absatou
Publikováno v:
Clinical and Vaccine Immunology. 18:435-443
The serogroup A meningococcal conjugate vaccine MenAfriVac has the potential to confer herd immunity by reducing carriage prevalence of epidemic strains. To better understand this phenomenon, we initiated a meningococcal carriage study to determine t
Autor:
Isaïe Medah, Sarah A. Meyer, Jean Ludovic Kambou, Amadou Fall, Issaka Yaméogo, Kathleen Wannemuehler, Thomas A. Clark, James L. Goodson, Nancy E. Messonnier, Brendan Flannery, Ryan T. Novak, Mamoudou Harouna Djingarey, Amanda C. Cohn, Fabien Diomandé
A new serogroup A meningococcal conjugate vaccine (PsA-TT, MenAfriVac™) has been developed to combat devastating serogroup A Neisseria meningitis (MenA) epidemics in Africa. A mass immunization campaign targeting 1-29 year olds was conducted in Bur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1cc31cd1f31d2404bf3d85aaf6557e0
https://europepmc.org/articles/PMC5755366/
https://europepmc.org/articles/PMC5755366/
Autor:
Kadidja Gamougam, Nehemie Mbakuliyemo, Denis Kandolo, Nancy E. Messonnier, James M. Stuart, F. Marc LaForce, Jean-Marc Collard, Paul A. Kristiansen, Ryan T. Novak, Doumagoum M. Daugla, William Perea, Brian Greenwood, Fabien Diomandé, Carol Tevi-Benissan, Mamoudou Harouna Djingarey, Marie-Pierre Preziosi, O. Walker, Thomas A. Clark, Dominique A. Caugant, Leonard W. Mayer
Publikováno v:
Clinical Infectious Diseases
Clinical Infectious Diseases, Oxford University Press (OUP), 2015, 61 (suppl_5), pp.S467-S472. ⟨10.1093/cid/civ499⟩
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases, Oxford University Press (OUP), 2015, 61 (suppl_5), pp.S467-S472. ⟨10.1093/cid/civ499⟩
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
International audience; Background. During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010–2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0f832aac82940364ba93875da5c003
https://researchonline.lshtm.ac.uk/id/eprint/2551457/1/civ499.PMC4639484.pdf
https://researchonline.lshtm.ac.uk/id/eprint/2551457/1/civ499.PMC4639484.pdf
Autor:
Christiane Adjé-Touré, Ebi Bile, Terence Chorba, John N. Nkengasong, Marie-Yolande Borget, Mireille Kalou, Fabien Diomandé
Publikováno v:
Journal of Clinical Virology. 32:60-66
Objective: We evaluated the performance of three genotypic assays to detect resistant mutations among HIV-1 infected patients with known antiretroviral drug resistance profile in Abidjan, Cote d'Ivoire, most of whom had the circulating recombinant fo